Enzalutamide
Onco
Daily
Twitter
Facebook
Youtube
RSS Feed
Linkedin
Facebook
RSS
Twitter
Youtube
Linkedin
July, 2024
July 2024
M
T
W
T
F
S
S
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
« Jun
Enzalutamide
Jun 24, 2024, 01:07 |
Blog
Yüksel Ürün: Our comment about 'Cardiovascular Events and Androgen Receptor Signaling Inhibitors in Advanced Prostate Cancer'
Yüksel Ürün shared on X: "Our comment about 'Cardiovascular Events and Androgen Receptor Signaling Inhibitors in…
Jun 6, 2024, 10:53 |
Insight
Earle Burgess: The best part of the oral prostate cancer session at ASCO24
Earle Burgess, Genitourinary Medical Oncologist, Atrium Health Levine Cancer Institute, shared a post on LinkedIn: “What…
Jun 4, 2024, 04:53 |
Insight
Earle Burgess: Fascinating preliminary phase I trial data in mCRPC at ASCO24
Earle Burgess, Genitourinary Medical Oncologist at Atrium Health Levine Cancer Institute, shared a post on LinkedIn:…
Apr 19, 2024, 20:03 |
Insight
Piotr Wysocki: BRCA1/2 mutations represent a poor prognostic factor for mCRCP patients - underscoring the need to use PARPi as soon as possible
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Apr 15, 2024, 16:45 |
Drugs
NCCN 2024 Prostate Cancer Guidelines Update by Maria Natalia Gandur Quiroga
Maria Natalia Gandur Quiroga shared a post on X: “NCCN 2024 Prostate Cancer Guidelines Update.…
Apr 15, 2024, 14:41 |
Drugs
Piotr Wysocki: The [177Lu]Lu-PSMA-617 plus enzalutamide combination is active and safe in mCRPC patients, but is it really an option for first-line treatment?
Piotr Wysocki, Professor of Medicine and Head of the Department of Oncology at Jagiellonian University…
Mar 15, 2024, 18:07 |
Insight
Talazoparib in Combination With Enzalutamide for Prostate Cancer - FDA Oncology
FDA Oncology posted on X/Twitter: "FDA Approval Summary: Talazoparib in Combination With Enzalutamide for Treatment…
Jan 31, 2024, 18:28 |
Drugs
Day 1 of GU24 ASCO Highlights by Oncology Brothers
Oncology Brothers shared on their X/Twitter page: "Day 1 GU24 ASCO Highlights 1. CONTAC02: Atezo/Cabo…
Dec 6, 2023, 13:54 |
Insight
Yüksel Ürün: The TALAPRO-2 trial shows a promising combo of talazoparib and enzalutamide for metastatic castration-resistant prostate cancer with HRR gene alterations
Yüksel Ürüna, Professor at Ankara University School of Medicine, shared on X/Twitter: "The TALAPRO-2 trial shows…
Nov 21, 2023, 14:18 |
Drugs
5 new drug indications by FDA Oncology in the last 10 days - Oncology Brothers
Quoting Oncology Brothers on X/Twitter: "What just happened? 5 new drug indications by FDA Oncology…
Nov 19, 2023, 16:51 |
Drugs
Karine Tawagi: New U.S. FDA approval for Enzalutamide in BCR prostate cancer
Karine Tawagi, Assistant Professor of Clinical Medicine and Associate Program Director at the University of…
Aug 25, 2023, 18:22 |
Insight
Earle Burgess: Which newly diagnosed metastatic castrate-sensitive prostate cancer patients need to add docetaxel chemotherapy to an ADT + ARPI doublet?
Quoting Earle Burgess, Genitourinary Medical Oncologist and Clinical Researcher at Atrium Health, Levine Cancer Institute,…
Jun 21, 2023, 18:41 |
Drugs
So pleased (& a little proud) to see U.S. FDA approval of Enzalutamide & Talazoparib in HRR-deficient 1L mCRPC
In a post by Arun Azad on Twitter, it says, "So pleased (& a little…
All:
13
Posts:
1 - 100
TRANSiTION - Exclusive Train the Trainers Programme 2024
ASCO IDEA - Life-changing experience for the early-career oncologists in LMICs
Gemma Peters: The new government has an opportunity to fix our broken cancer care system
Blending Science and Compassion: Exclusive Conversation with ASCO President-Elect Eric J. Small
OncoDaily at ASCO 2024: OncoDaily Party, Yvonne Award and much more
Facebook
RSS Feed
Twitter
Linkedin
Youtube